Guggenheim Cuts Nanobiotix (NASDAQ:NBTX) Price Target to $8.00

Nanobiotix (NASDAQ:NBTX - Get Free Report) had its price objective reduced by equities researchers at Guggenheim from $12.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price target suggests a potential upside of 165.25% from the stock's current price.

Separately, UBS Group raised shares of Nanobiotix to a "hold" rating in a research report on Monday, February 17th.

Nanobiotix Stock Down 0.1 %

NBTX stock traded down $0.00 during trading on Friday, reaching $3.02. 83,669 shares of the stock were exchanged, compared to its average volume of 19,945. The firm's 50 day moving average is $3.57 and its 200 day moving average is $3.74. Nanobiotix has a twelve month low of $2.76 and a twelve month high of $7.51.

Institutional Investors Weigh In On Nanobiotix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC bought a new stake in shares of Nanobiotix in the 4th quarter worth $29,000. Millennium Management LLC bought a new stake in Nanobiotix in the 4th quarter worth about $39,000. Jane Street Group LLC purchased a new stake in Nanobiotix in the 4th quarter valued at about $73,000. Finally, OLD Mission Capital LLC bought a new position in shares of Nanobiotix during the 4th quarter worth approximately $139,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.